News | July 09, 2024
Olink announces receipt of CMA clearance for proposed acquisition by Thermo Fisher
Shares and American Depositary Shares of Olink for $26.00 per Share
Shares and American Depositary Shares of Olink for $26.00 per Share
Comprehensive clinical development programs being initiated for each investigational candidate
The products are slated to be manufactured at the Ankleshwar facility and is expected to start contributing meaningfully to the revenue from FY25
The product is expected to start contributing meaningfully to the revenue from FY25
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%
On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
The two companies will work together for the Prospective Evaluation of OrionAI – a revolutionary AI-based Diagnostic Assistant for Histological Examination of a variety of solid tumours beginning with Head and Neck Squamous Cell Carcinoma (HNSCC) Cancer
Using Orion, pharmaceutical and biotechnology companies, as well as any industrial researcher who wishes to perform electronic structure calculations, can gain access to elastic and flexible computational resources in the Cloud
Darolutamide is developed jointly by Bayer and Orion Corporation
Subscribe To Our Newsletter & Stay Updated
